Publications

Journal Article
Research Support, Non-U.S. Gov't Review
Ppublish 904 citations
Electronic publication date
July 19, 2002

View on Pubmed.gov 12093006 | View on doi.org 10.1038/nri819

Cytotoxic T lymphocytes: all roads lead to death.

Search for publications in this journal Nat Rev Immunol - 2(6):401-9

Abstract

Cytotoxic T lymphocytes (CTLs) provide potent defences against virus infection and intracellular pathogens. However, CTLs have a dark side--their lytic machinery can be directed against self-tissues in autoimmune disorders, transplanted cells during graft rejection and host tissues to cause graft-versus-host disease, which is one of the most serious diseases related to CTL function. Although this duplicitous behaviour might seem contradictory, both beneficial and detrimental effects are the result of the same effector proteins. So, an understanding of the mechanisms that are used by CTLs to destroy targets and a knowledge of pathogen immune-evasion strategies will provide vital information for the design of new therapies.

References

No references provided.

Cited by 904 citations (total)

Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts.

Electronic publication date September 4, 2004

Search for publications in this journal Am J Pathol

Jonathan C Choy [...] David J Granville et al.

T cell-induced endothelial injury is an important event in the development of transplant vascular disease (TVD), the leading expression of...

Journal Article

Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection.

Electronic publication date December 16, 2004

Search for publications in this journal J Virol

Miriam Rode [...] Markus M Simon et al.

In this report we questioned the current view that the two principal cytotoxic pathways, the exocytosis and the Fas ligand...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances